Hepatocellular Carcinoma Tumor Marker Panel

The µTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably.

The AFP-L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases.
Patients with elevated serum AFP-L3 percent should be more intensely evaluated for evidence of hepatocellular carcinoma since elevated values have been shown to be associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

For pregnant females, the result is not interpretable as a tumor marker.

The des-gamma-carboxy prothrombin (DCP) assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated DCP values have been shown to be associated with an increased risk for developing hepatocellular carcinoma. Patients with elevated serum DCP should be more intensely evaluated for evidence of hepatocellular carcinoma. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.